-$0.02 (-1.59%)
01:56AM (15 mins delay)
Oct 09, 2009 - 6:32 AM EDT
Mike Havrilla submits:Inovio Biomedical (AMEX: INO) is developing a robust pre-clinical and early clinical stage pipeline of innovative DNA-based vaccines and therapeutics that target cancer, influenza, and other infectious diseases (e.g. HIV) based on its SynCon DNA vaccine construct and electroporation DNA delivery technology platforms. Click here to visit Inovio’s corporate profile page at OneMedPlace.com, which also includes a CEO video interview.
Inovio’s electroporation-delivered DNA-based vaccines / therapeutics are based on the application of controlled electrical pulses at the molecular level (i.e. this is not like electro-shock therapy or touching a live electric wire!) to create temporary pores in cell membranes and enable increased cellular uptake. This delivery method is expected to yield safer results as compared to alternate gene therapy approaches that may utilize viruses to deliver genetic material to the target tissue or tumor. The Company also has access to formulation and manufacturing technology / IP through its controlling ownership in VGX Pharmaceuticals.
Source: Seeking Alpha (Oct 09, 2009 - 6:32 AM EDT)
© 2009 UpDown. All Rights Reserved.
Make a suggestion for this page
Data powered by QuoteMedia (Terms of Use). Data delayed 15 minutes unless otherwise indicated.
